AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02430077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical to Obeticholic Acid - placebo drug
Trial: NCT01548690
Drug: Ornithine Phenylacetate
RxNorm normalized name: phenylacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 36 patients will be enrolled into 2 groups \[\~18 with minimal renal dysfunction (Cohort 1) \& \~18 w/ comprised renal function (Cohort 2)\] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (\~6 Cohort 1 \& \~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4).
Trial: NCT03698734
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
Trial: NCT03510793
Drug: balanced anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia
Trial: NCT03510793
Drug: Total intravenous anesthesia
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
Trial: NCT01585129
Drug: No postpartum antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
Trial: NCT01812044
Drug: subtenons control - 0.5 cc of Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00758784
Drug: bromfenac ophthalmic solution 0.06%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromfenac ophthalmic solution 0.06% bilaterally twice a day
Trial: NCT01802359
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
Trial: NCT00645086
Drug: clarithromycin immediate-release tablets
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
Trial: NCT00474916
Drug: KRN5500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
Trial: NCT00474916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline given as dose escalation for placebo
Trial: NCT00184587
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03373019
Drug: Chidamide combined with R-GDP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
Trial: NCT02547623
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone eye drops 1%
Trial: NCT00826514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo, single dose
Trial: NCT00116454
Drug: 131 I-lipiodol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
Trial: NCT03756090
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
Trial: NCT03756090
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
Trial: NCT01021943
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
Trial: NCT01021943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of the subjects will be assigned to receive placebo for 6 months
Trial: NCT01859455
Drug: LGT209 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active experimental drug
Trial: NCT01859455
Drug: LGT209 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active experimental drug
Trial: NCT01859455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01859455
Drug: Statins (atorvastatin or simvastatin)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stable doses of atorvastatin or simvastatin
Trial: NCT02712775
Drug: Minocycline (yes/no)
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02712775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT03040024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
Trial: NCT00635622
Drug: Placebo control substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
Trial: NCT01381536
Drug: GSK1550188 1mg/kg or 10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV one shot
Trial: NCT04046302
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.
Trial: NCT04046302
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
Trial: NCT00227058
Drug: Orotic acid and Glutathione-(Nutritional Supplements)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00206570
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00264277
Drug: Vitamin K antagonist (Coumarin anticoagulants)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02646904
Drug: CERCHIO 10 mg/ml OS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days.
Trial: NCT01740362
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg (2 x 5 mg tablets), single dose
Trial: NCT02112110
Drug: [13C]-BMS-791325
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02028949
Drug: Zavedos®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00805207
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
Trial: NCT00805207
Drug: glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
Trial: NCT00002676
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002676
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01403116
Drug: Oral testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
Trial: NCT01403116
Drug: topical testosterone gel
RxNorm normalized name: testosterone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
Trial: NCT02469246
Drug: ABC/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/300 mg FDC tablets administered orally once daily
Trial: NCT02469246
Drug: ABC/3TC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT02469246
Drug: F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT01883505
Drug: Levodopa and carbidopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous continuous administration
Trial: NCT01883505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous continuous administration
Trial: NCT01907165
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00468897
Drug: RSG XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
Trial: NCT00216034
Drug: Krestin (PSK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
Trial: NCT04626622
Drug: Kagocel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators could prescribe other drugs in frame of routine clinical practice
Trial: NCT04626622
Drug: No one
RxNorm normalized name: ALCOHOL 70 g in 100 mL TOPICAL GEL [d.therapino one step hand sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
Trial: NCT01941225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration
Trial: NCT06367322
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP.~Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy.
Trial: NCT00361530
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03590860
Drug: LY3322207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by SC injection
Trial: NCT03590860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by SC injection
Trial: NCT01780233
Drug: Fentanyl 400 µg sublingual spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01780233
Drug: Actiq® 400 µg transmucosally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
Trial: NCT01780233
Drug: Fentanyl citrate injection 100 µg intravenously
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03530514
Drug: REGN4461
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN4461
Trial: NCT03530514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching REGN4461
Trial: NCT02153840
Drug: PSORI-CM01（YXBCM01） granule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02153840
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02455908
Drug: Proleukin®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01455649
Drug: calcineurin inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
Trial: NCT00560833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02359721
Drug: tablet clarithromycin 500 mg (Clarino-500) orally
RxNorm normalized name: clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally
Trial: NCT03431168
Drug: Azithromycin/TMPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
Trial: NCT03431168
Drug: Placebo/TMPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
Trial: NCT03861000
Drug: [C-11]T-1650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radio-labeled drug
Trial: NCT03861000
Drug: BPN14770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selective compound
Trial: NCT02140125
Drug: ASP2408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous administration
Trial: NCT02140125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous administration
Trial: NCT01123889
Drug: corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
Trial: NCT01817257
Drug: Low Molecular Weight Heparin (LMWH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
Trial: NCT06556108
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Trial: NCT00525252
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be orally administered for 12 consecutive weeks
Trial: NCT00997074
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
Trial: NCT01128985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
Trial: NCT00188188
Drug: quinipril
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06190483
Drug: Ascorbic Acid 50 Mg Oral Tablet
RxNorm normalized name: ascorbic acid 50 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
Trial: NCT02884635
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
Trial: NCT06417515
Drug: Xiao-Yao-San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who received Xiao-Yao-San 9 g/day (Kaiser Pharmaceutical Co. Ltd.) were selected for the Xiao-Yao-San group by traditional Chinese doctor with 8 years of experience.
Trial: NCT00000257
Drug: 0% N2O and 10% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000257
Drug: 0% N2O and 20% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000257
Drug: 0% N2O and 30% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000257
Drug: 0% N2O and 40% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01640301
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03077282
Drug: Prasaprohyai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
Trial: NCT04073550
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib blank analog capsule.
Trial: NCT02926690
Drug: OTS167PO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single arm, no competitor
Trial: NCT00332904
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
Trial: NCT01625806
Drug: RO4602522
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT00719199
Drug: IMO-2055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC weekly injections
Trial: NCT00719199
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given day 1 of each cycle
Trial: NCT00929240
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
Trial: NCT02209506
Drug: MLN3126
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN3126 tablets
Trial: NCT02209506
Drug: MLN3126 Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN3126 placebo-matching tablets
Trial: NCT00435084
Drug: APO866
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00416533
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00332787
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03634982
Drug: RMC-4630
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMC-4630 for oral administration
Trial: NCT02413658
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical use of phenytoin solution on dressings of split thickness skin graft sites.
Trial: NCT00584974
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01644877
Drug: DAS181 dry powder, formulation F02
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01644877
Drug: Lactose Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04469491
Drug: inhaled type I interferon
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
Trial: NCT02934607
Drug: Symbicort pMDI with spacer device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
Trial: NCT02934607
Drug: Symbicort pMDI without spacer device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
Trial: NCT00454233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01870635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
Trial: NCT04576312
Drug: UNI911 inhalation 1% and intranasal spray 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.